Cardiovascular Disease
Single excess weight measurement ‘does not seal one’s fate’ for heart-related events
BOSTON — Younger adults are at greater cardiovascular disease risk if they have obesity for 10 years, but a single excess weight measurement does not predict risk for heart-related events over time, according to data presented at ENDO 2024.
Adults with class II to III obesity may have increased cardiac outcomes
Adults with class II to III obesity may have an increased risk for poor cardiac outcomes but not kidney risk after adjusting for potential confounders, according to multicenter data.
Regular fish oil use may pose cardiovascular risk in those with no prior CVD
Regular use of fish oil supplements was tied to an increased risk of stroke and atrial fibrillation in adults with no prior CVD, according to results of a large prospective cohort study published in BMJ Medicine.
Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk
Use of the drug semaglutide in patients with type 2 diabetes significantly reduced the risk of major kidney disease events, cardiovascular outcomes and all-cause mortality vs. placebo, newly published data show.
Step- and time-based exercises equally beneficial in reducing CVD, mortality risks
Both step counts and time-based physical activity reduced the risks of death and CVD among women aged 62 years and older, a study in JAMA Internal Medicine showed.
Men at higher risk for diabetes-related complications than women
Men were at greater risk for several complications associated with type 1 and type 2 diabetes compared with women, according to results published in the Journal of Epidemiology & Community Health.
Prevalence of advanced fibrosis similar in lean, non-lean MASLD, linked to genetic risk
WASHINGTON — The risk for advanced fibrosis was similar among patients with lean and non-lean metabolic dysfunction-associated steatotic liver disease and may be associated with genetic risk, according to data at Digestive Disease Week.
GLP-1RA use in MAFLD, obesity lowers mortality, ‘provides cardiovascular benefits’
WASHINGTON — Patients with obesity and metabolic dysfunction-associated fatty liver disease taking glucagon-like peptide-1 receptor agonists had lower risk for all-cause mortality and major cardiovascular events, according to a presenter.
Are drugs or surgery superior for obesity treatment?
Today, we are closer than ever to achieving the weight loss seen with bariatric surgery, and we are starting to see emerging evidence of cardiovascular risk reduction, type 2 diabetes remission, improvement in heart failure with preserved ejection fraction (HFpEF) and more. This “new” class of medications has been around for more than 18 years. We know the safety profiles; they are manageable.
Low testosterone tied to increased risk for mortality, CVD events
Men with low testosterone concentrations had a higher risk for all-cause mortality, and those with very low testosterone also had an increased risk for CVD mortality, a study in Annals of Internal Medicine showed.